Mary B. Daly, MD, PhD, FACP
Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111-2497
Video: Mary B. Daly, MD, PhD, FACP
Top Doctors 2015
- Betsy Billigmeier - Risk Assessment Program Patient Stories, Ovarian Cancer Patient Stories
- Deena Dell - Stage 0 Breast Cancer (DCIS) Patient Stories
- Amy Dysart - Risk Assessment Program Patient Stories, Risk Assessment Program Breast Cancer Patient Stories
- Deborah Davis Huberfeld - Breast Cancer Patient Stories
- Denise Portner - Breast Cancer Patient Stories, Risk Assessment Program Breast Cancer Patient Stories
- Linda Snow - Breast Cancer Patient Stories, Triple Negative Breast Cancer
- Linda Stockman-Vines - Breast Cancer Patient Stories, Risk Assessment Program Breast Cancer Patient Stories, Risk Assessment Program Patient Stories
- Jane Tervooren - Breast Cancer Patient Stories, Plastic and Reconstructive Surgery Patient Stories, Risk Assessment Program Breast Cancer Patient Stories, Risk Assessment Program Patient Stories
(Dec 12, 2013)
Fox Chase Clinical Genetics Chair Comments on Early Cancer Detection in Pregnant Women
Hem/Onc Today, June 17, 2015
Mary B. Daly, MD, PhD, FACP, Chair of Clinical Genetics at Fox Chase Cancer Center, offered expert commentary to Hem/Onc Today about a JAMA Oncology studyon prenatal testing to detect cancer in pregnant women. The study involved noninvasive testing of maternal plasma cell-free DNA in more than 4,000 pregnant women—three of whom were found to have suspected cancers and were later diagnosed with cancer after further tests. “This is an interesting article,” noted Dr. Daly, who was not involved in the study, explaining that the “use of plasma-derived DNA — as opposed to cell-derived DNA — is a field of active investigation as a way to detect tumors early, or to monitor treatment.”
Do You Want to Know?
A WHYY-produced video examines how Fox Chase’s Risk Assessment Program can help people learn about their risk. In the 4-minute video, genetic counselor Andrea Forman explains how she maps the family history of people like Carlette Knox, a breast cancer patient who discovered her BRCA gene mutation through the program. RAP founder Mary Daly, MD, PhD, and genetics lab manager Betsy Bove, PhD, also describe the program, which recently celebrated its 20th anniversary. Click here to view the video on Newsworks.org.
Chair, Clinical Genetics
Timothy R. Talbot Jr. Chair for Cancer Research
Cancer Prevention and Control Program
Oncology, University of Texas Health Center
I consider it an honor and a privilege to have the opportunity to accompany my patients on their cancer journey. I am allowed to witness their strength and courage, to be exposed to the devotion of their families and friends, and to become part of their lives in a very special way.
I like to approach every patient encounter as an educational experience. It is an opportunity for me to share with each patient the latest information about their cancer and treatment, and give them the tools they need to make informed decisions. It is also an opportunity for them to teach me something about themselves, about their lives and families, and how they cope with illness and promote their own health. I always feel both drained and enriched after a day in clinic.
I joined the staff of Fox Chase Cancer Center in 1989. I currently serve as the Chair of the Department of Clinical Genetics, where I hold the Timothy R. Talbot Jr. Endowed Chair in Cancer Research. I have a joint appointment in the Medical Science Division.
My focus is women's health and I am the founder of the Margaret Dyson Family Risk Assessment Program (now Risk Assessment Program), evaluating preventive approaches to breast and ovarian cancer. My primary areas of research include the epidemiologic and genetic aspects of breast and ovarian cancer, and the translation of this information into effective cancer prevention. As director of the Ovarian Cancer Consortium for Research and Surveillance (OCCRS), I have initiated studies of ovarian cancer screening methods, quality of life after prophylactic (preventive) surgery and serum biomarkers of breast cancer risk.
As principal investigator of the Cooperative Family Registry for Breast Cancer Studies, I am collaborating with institutions worldwide to study the patterns of familial breast and ovarian cancer, gene-environment interactions and the development of novel, genetic-based therapeutic and preventive strategies.
I have been recognized as a leader in the design of educational programs in cancer genetics and cancer risk for both high-risk individuals and for their health-care providers. In addition, I serve as the principal investigator of the NSABP breast cancer prevention trials (P1 and STAR).
University of North Carolina at Chapel Hill School of Medicine, 1978 (PhD in Epidemiology, 1973)
Internal Medicine, University of Texas Health Center
Oncology, University of Texas Health Center
Honors and Awards
Philadelphia Magazine Top Docs, 2009-2015
Breast Cancer; Risk Assessment; Human Genetics; Ovarian Cancer; Genetic Testing; Epidemiology